Side Effects of Mounjaro: What Clinical Trials and NHS Guidance Tell Us

What the SURMOUNT trial data actually showed about side effects

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity to tirzepatide or placebo over 72 weeks. Side-effect data from that programme gives us the clearest picture of what to expect at scale. Gastrointestinal events were by far the most common reason people reported symptoms: nausea affected roughly a third to half of participants depending on dose, with diarrhoea, vomiting, and constipation each reported at meaningful rates too. The important context is that the majority of these were graded mild or moderate, and most resolved without stopping treatment.

Rates were higher at the start of each new dose level and typically settled. That pattern is one reason the licensed schedule begins at 2.5 mg — the opening weeks are about letting your system adjust, not about therapeutic effect. For a fuller breakdown of how each individual side effect presents, the complete Mounjaro side effects guide covers each one in more detail.

Beyond the gut, the trials recorded injection-site reactions, fatigue, headache, and dizziness in a smaller proportion of people. Hair thinning has been raised by patients; the evidence on hair loss and Mounjaro puts that in context. These less-discussed effects are worth knowing about, even if the headlines rightly focus on GI symptoms.

The side effects that warrant urgent medical attention

Most of what people experience on Mounjaro is unpleasant but not dangerous. A smaller set of symptoms needs prompt medical assessment.

Pancreatitis is the one the MHRA flagged specifically: in its January 2026 Drug Safety Update covering GLP-1 medicines, the regulator highlighted acute pancreatitis as an infrequent but potentially serious reaction. The symptom to act on is severe, persistent stomach pain that may radiate through to the back, with or without vomiting. If that happens, stop eating and drinking and get medical help the same day, do not wait to see if it passes.

Other signs that need prompt attention: gallbladder symptoms (upper-right abdominal pain, particularly after eating), significant dehydration from prolonged vomiting or diarrhoea, any signs of a serious allergic reaction (swelling of the face or throat, difficulty breathing, rapid heart rate), and low mood or thoughts of self-harm. The MHRA Yellow Card scheme exists precisely so that patients, not just clinicians, can flag serious reactions, it takes under a minute to submit a report online and contributes directly to post-market safety monitoring.

If you are unsure whether a symptom is serious, a quick check: can you keep fluids down? Is the pain constant rather than coming and going? Has it lasted more than 24 hours? Those three questions help triage what needs same-day attention versus what can wait for a scheduled call with your prescriber.

Less-obvious side effects people ask about most

Beyond the trial headline numbers, a few specific side effects generate a lot of questions. Burping is one, it sounds minor but can be persistent and disruptive; why Mounjaro causes burping and what helps is covered separately. Loose stools and diarrhoea are another recurring concern, particularly in the first weeks; the detail on diarrhoea as a Mounjaro side effect explains the mechanism and when it typically resolves.

Liver-related questions come up too, especially among people with existing fatty liver disease. Mounjaro and liver side effects addresses what the evidence shows and what monitoring is appropriate. For people who want a structured summary before starting, the five Mounjaro side effects most commonly reported offers a concise reference point.

The broader picture: Mounjaro's side-effect profile is well-characterised at this point, both from SURMOUNT and from real-world prescribing data accumulating since UK licensing. It is not a medicine without risk. It is also not one where side effects are unpredictable or unmanaged, which is exactly why ongoing clinical oversight matters.

How prescribing practice reduces side-effect burden

The dose titration schedule exists for a reason. Starting at 2.5 mg gives the body time to adapt to slowed gastric emptying before the dose with meaningful appetite effect is reached. Most clinicians will hold a dose level for longer than four weeks if side effects are significant rather than push through, and that flexibility is built into how responsible prescribers manage treatment.

Practical habits make a difference too: smaller meals, eating slowly, avoiding very fatty or spicy food in the first weeks, and staying well-hydrated all reduce GI burden. These are not workarounds; they are evidence-backed adjustments that the NHS tirzepatide page specifically mentions alongside the medicine itself.

At nume, side effects are part of the consultation, not a footnote. A GPhC-registered prescriber reviews your answers the same day, and our aftercare team is available seven days a week if something comes up after you start. If you have questions about your specific health history and how it intersects with this medicine's profile, speaking to our prescribers is the right next step. You can also read more about Mounjaro as a treatment before deciding whether to go ahead.